CoChat

Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC)

Morris, J. C., Shapiro, G. I., Tan, A. R., Lawrence, D. P., Olencki, T. E., Dezube, B. J., Hsu, F. J., Reiss, M., Berzofsky, J. A. · 2008 · Journal of Clinical Oncology
Cited by 78

The DOI matches its Crossref record.

Abstract

9028 Background: TGFβ is a pleiotropic cytokine that normally helps maintain tissue homeostasis. However, in advanced cancers, TGFβ is often overexpressed and associated with higher pathologic grade, increased frequency of metastases, and poorer survival. In such cancers, TGFβ signaling is often altered, and TGFβ becomes a tumor promoter by stimulating tumor cell proliferation/migration/invasion and angiogenesis, by activating stromal cells, and by suppressing anti-tumor immunity. GC1008 is a human IgG4 MAb capable of neutralizing TGFβ isoforms 1, 2, & 3. We report the results of an ongoing, first in cancer, multi-center trial examining the safety and effectiveness of GC1008. Methods: Cohorts of patients (Pts) with advanced MM or RCC who had failed ≥ 1 prior therapy (Tx) were treated with GC1008 at 1 of 6 dose levels (0.1, 0.3, 1, 3, 10 or 15mg/kg) in a 3+3 design. If no DLTs occurred within 28 days of the first dose, 3 additional doses were administered 2wks apart. Tumor response was determined by RECIST. Extended Tx (GC1008 q2wk x 4) was offered to Pts achieving SD, PR, or CR. Results: 22 Pts (21 MM, 1 RCC) were treated in Phase I, including 6 Pts at 15mg/kg. No DLTs were observed and the highest dose level of GC1008, 15mg/kg, was determined to be a safe dose. Adverse events reported as at least possibly related to GC1008 included skin rash (including 2 cases of eruptive keratoacanthomas), fatigue, headache, epistaxis, gingival bleeding, and GI symptoms; all were grade 1 or 2. 9/22 Pts reported SAEs, most of which were related to underlying disease. To date, the only SAE considered possibly related to GC1008 Tx is a well-differentiated squamous cell cancer of the skin in a Pt with a history of this cancer. So far, 5 Pts achieved SD or better and received extended Tx. Of these responders, 3/5 Pts had mixed responses with shrinkage of liver metastases and other sites; 1/5 Pts with skin disease achieved a PR with >75% reduction of target lesions. Conclusion: GC1008 is well tolerated and neutralization of TGFβ holds promise as a novel cancer Tx. A Phase II protocol expansion is planned for Pts with metastatic MM. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Genzyme Genzyme Genzyme Genzyme Genzyme

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.26.15_suppl.9028

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 78

Metadata

Authors
Morris, J. C., Shapiro, G. I., Tan, A. R., Lawrence, D. P., Olencki, T. E., Dezube, B. J., Hsu, F. J., Reiss, M., & Berzofsky, J. A.
Venue
Journal of Clinical Oncology
Published
2008-05-20
Volume
26
Issue
15_suppl
Pages
9028-9028
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2306753419
Cited by
78
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). https://app.cochat.ai/papers/10.1200/jco.2008.26.15_suppl.9028
The paper
Morris, J. C., Shapiro, G. I., Tan, A. R., Lawrence, D. P., Olencki, T. E., Dezube, B. J., Hsu, F. J., Reiss, M., & Berzofsky, J. A. (2008). Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.26.15_suppl.9028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.